source
- Novartis halts ALS drug VHB937 after phase 2 trial fails to meet endpointsNovartis announced it is stopping development of its ALS candidate VHB937 after the phase 2 Astrals trial did not meet its primary or secondary endpoints. The study enrolled 251 patients with earl…
- Senator Todd Young urges White House to appoint biotech leader amid rising Chinese innovationSenator Todd Young, chair of the National Security Commission on Emerging Biotechnology, told Fierce he is concerned about China’s expanding role in biopharma. The commission notes that Chinese co…